Max Biopharma, Inc.

MAX BioPharma is a privately-held, preclinical-stage California-based biopharmaceutical company pioneering the field of Oxysterol Therapeutics. The company develops novel small molecule lipid drug candidates — oxysterols — for intervention in debilitating human diseases including metabolic dysfunction-associated steatohepatitis (MASH), oncology indications (lung and pancreatic cancer), inflammatory diseases, and bone disorders. Its lead compound Oxy210 is an orally bioavailable oxysterol with antifibrotic and anti-inflammatory properties being developed for MASH. MAX BioPharma's intellectual property portfolio is supported by collaborations with UCLA, Emory School of Medicine, Case Western Reserve, and Ohio State University, with funding from CIRM, NIH SBIR/STTR programs (NIA, NHLBI, NIDDKD, NCI), and strategic partnerships including Technomark Life Sciences and Metaba.